
Jerry DJ, Butel JS, Donehower LA, Paulson EJ, Cochran C, Wiseman RW, Medina D:
Infrequent p53 mutations in 7,12-dimethylbenz[a]anthracene-induced
mammary tumors in BALB/c and p53 hemizygous mice.
Molecular Carcinogenesis 1994 Mar;9(3):175-83
ABSTRACT
We conducted experiments to determine if p53 alterations, which are
frequent in human breast cancers, were also common in murine mammary
tumors. In 13 mammary tumors from 7,12-dimethylbenz[a]anthracene
(DMBA)-treated BALB/c mice were immunohistochemically analyzed for
overexpression of p53; p53 protein was not detectable. Three of the
tumors were established as cell lines in vitro. p53 protein was
rarely detected at passage 4 in these lines but was overexpressed by
passage 8 in two of them. The p53 nucleotide sequence was shown to
be wild type in one primary mammary tumor and in the two
p53-overexpressing cell lines. One cell line that overexpressed p53
in vitro was implanted into BALB/c mice. The resulting tumors
retained the wild-type p53 nucleotide sequence but no longer
expressed detectable levels of p53 protein, suggesting that the
overexpression of wild-type p53 was related to in vitro culture
conditions. The effect of DMBA on mammary-tumor development was also
tested in mice rendered hemizygous for p53. These mice and wild-type
littermate controls had no differences in susceptibility to
induction of mammary tumors by oral administration of DMBA.
Furthermore, Southern blot hybridization detected no gross
alterations in the wild-type p53 allele in mammary tumors from the
p53-deficient mice. Point mutation of the wild-type p53 allele was
also infrequent in the DMBA-induced mammary tumors from hemizygous
p53 mice; it occurred in only one of seven tumors. Thus, the p53
gene is apparently not a primary target for genetic alterations in
DMBA-induced mammary tumors. Next, we examined mammary tumors
derived from D1 and D2 transplantable hyperplastic alveolar nodule
(HAN) outgrowths, which rapidly form tumors containing Ha-ras
mutations after DMBA treatment. As ras and p53 mutants can cooperate
in transformation, we examined whether D1 and D2 HAN outgrowths have
p53 mutations. Unlike in the DMBA-induced primary mammary tumors,
nuclear p53 accumulation was observed frequently (10 of 14) in
tumors that arose from D1 and D2 HAN outgrowths. Direct sequencing
of the entire coding region of the p53 cDNA from six D1 and D2
tumors confirmed that the sequence was wild type. Although wild-type
p53 was retained in both DMBA-induced mammary tumors and mammary
tumors derived from D1 and D2 preneoplastic outgrowths, wild-type
p53 overexpression was detected only in D1 and D2 tumors. Therefore,
D1 and D2 tumors appear to arise by a pathway in which p53
expression is altered, whereas DMBA induction affects a different
pathway that does not require such alteration.